Skip to content

Home
IOncology
Infectious Desease Frontier
IHepatology
Hematology Frontier
Conference topics
Experts Interviews
Informations
Live Broadcasting
Logout

Connecting Medical Expertise through Media

Search for:

Home
IOncology
Infectious Disease Frontier
International Hepatology
Hematology Frontier
Conference topics
Experts’ Interviews
Informations

Home
IOncology
Infectious Disease Frontier
International Hepatology
Hematology Frontier
Conference topics
Experts’ Interviews
Informations

Search for:

#ESMO2024

Home » #ESMO2024

ESMO 2024 | Dr. Dingwei Ye Presents Promising Data on BL-B01D1 for Advanced Urothelial Carcinoma

ESMO 2024 | Dr. Dingwei Ye Presents Promising Data on BL-B01D1 for Advanced Urothelial Carcinoma

Posted by

By Mourabit Halima 2024.11.15

At the ESMO 2024 Congress in Barcelona, Dr. Dingwei Ye from Fudan University Shanghai Cancer Center presented findings from a phase 2 study on BL-B01D1, a novel EGFR and HER3…

ESMO China Voice: Personalized ctDNA Methylation for Monitoring MRD Post-Liver Cancer Resection by Fan Jia, Jian Zhou & Xinrong Yang’s Team

ESMO China Voice: Personalized ctDNA Methylation for Monitoring MRD Post-Liver Cancer Resection by Fan Jia, Jian Zhou & Xinrong Yang’s Team

Posted by

By Lisa Cui 2024.10.28

Amidst the serene morning mist gracing the wutong trees and frost enhancing the ripeness of oranges, the 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) unfolds in…

Recent Posts

Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang
Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou
Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits
2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma
Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology

Recent Comments

Archives

Categories

Artificial intelligence
Hematology Frontier
Infectious Disease Frontier
International Hepatology
IOncology
Live broadcasting
Uncategorized
UroStream

LinkedIn
Twitter
Mail

Related Media:

Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
Paris, France